NDAORALTABLETPriority Review
Approved
Feb 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
3
Clinical Trials (3)
Lanreotide Combined With Telotristat Ethyl or Placebo for the First-line Treatment in Patients With Advanced Well Differentiated Small Intestinal Neuroendocrine Tumours (siNET) With Highly-functioning Carcinoid Syndrome
Started Apr 2020
0Small Intestinal NETCarcinoid Heart Disease
A Safety and Efficacy Study of XERMELO® + First-line Chemotherapy in Patients With Advanced Biliary Tract Cancer
Started Mar 2019
Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO
Started Jun 2017
Loss of Exclusivity
LOE Date
Feb 28, 2031
60 months away
Patent Expiry
Feb 28, 2031